Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

BACKGROUND: This investigator-initiated trial provided the justification for the phase III GRID study resulting in worldwide regulatory approval of regorafenib as a third-line therapy for patients with metastatic gastrointestinal stromal tumors (GIST). We report the genotype analyses, long-term safe...

Full description

Saved in:
Bibliographic Details
Published in:Ann Oncol
Main Authors: Ben-Ami, E., Barysauskas, C. M., von Mehren, M., Heinrich, M. C., Corless, C. L., Butrynski, J. E., Morgan, J. A., Wagner, A. J., Choy, E., Yap, J. T., Van den Abbeele, A. D., Solomon, S. M., Fletcher, J. A., Demetri, G. D., George, S.
Format: Artigo
Language:Inglês
Published: Oxford University Press 2016
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279099/
https://ncbi.nlm.nih.gov/pubmed/27371698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw228
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items